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CAMA 2002:
Were You There?
BY JAMES R. ALMAND, MD
"VVVTiat sights: Amsterdam,
W Rembrandt, flowers, mu-
seums, Van Gogh, canals, ports,
locks, beauty, windmills, culture,
history, atmosphere, Anne Frank,
wine, cheese, 800,000 bicycles,
2,500 houseboats, more canals
than Venice, tolerance, friend-
ship, cosmopolitan, narrow tall leaning
homes, tulips, a beautiful city, and an out-
standing, Aviation Medical International
meeting of 100-plus physicians from 26
countries.
If you weren't there,
then you missed an event
of significance to Interna-
tional Civil Aviation Medi-
cine. The venue, climate,
scenery, hotel, and pro-
gram were all so memo-
rable—right down to the
last sample of pastry and
Dutch chocolate each
evening! The "Grand Kraz"
hotel excelled in every facet
to ensure all amenities.
Your program planning and session com-
mittee spent many hours to ensure that all
details were perfect, and all scientific ses-
sions were marvelously conducted, with
Continued on page 5
Your Ex Says
BY SILVIO FINKELSTEIN, MD, MSc
CAMA PRESIDENT 1974-1975
In the fall of 1974, when taking over theAssociation from Leroy Wolever in Colo-rado Springs, it was difficult to envision
the significant changes and approaches that
civil aviation medicine would endure over
the next 28 years. As such, with great plea-
sure, we have witnessed (and hopefully con-
tributed) to improvements in flight safety.
In some way we have also contributed to the
concept and importance of human factors.
The need for internationalization of our ac-
tivities became readily apparent because
CAMA has a significant proportion of non-
US members and organizes international
meetings in response to such need.
CAMA members, as civil aviation medi-
cal examiners (AMEs in the States), (Medical
Examiners in ICAO's lingo) are indispensable
Practitioners of Aviation Medicine are
responsible for assisting in the selection
of appropriate personnel...
elements in the flight safety chain. The
magnitude of global aviation operations
strongly suggests that we should work hard
in improving our knowledge of human ca-
pabilities (performance and limitations) re-
lated to civil aviation. As monitors of the
human element in the system, we should
remember that human beings are necessary
for the design, development, operation, and
maintenance of aviation.
Practitioners of Aviation Medicine are re-
sponsible for assisting in the selection of
appropriate personnel by "selecting in" and
not "screening out," and for developing and
implementing good preventive medicine
practices to maintain an optimum level of
occupational health and safety. The two
Continued on page 15
/=Z/G7/7"PHYSICIAN November 2002
The President's Musings: The State of Our Association
BY ROBIN E. DODGE, MD
Ansterdam and the annualscientific meeting is nowofficially an event of the
past. The meeting, with representa-
tives of 26 countries, by all accounts,
was a huge success. The professional
attendance, exclusive of speakers, was
about 100, and there were 30 regis-
tered partners.
The program ran smoothly and
the evaluations reflect a high degree
of satisfaction with the program con-
tent. In fact, there were no negative
narrative comments received. The
total average program evaluation was
a 4.29 out of a possible 5. All those
who answered the question about at-
tending a future CAMA conference
responded in the affirmative.
In talking with executive vice-
president Jim Harris and members
of the Dutch organizing committee,
no one reports having heard any
negative comments.
The partner program
was also given very high
marks by the attending
spouses. The activities
were well thought out, in-
teresting, and enjoyable. I
wish to publicly thank all
those individuals involved
in the planning and executing of this
year's program and the speakers for
contributing so much to the success
of the meeting.
On reflection then, it seems that
for the fourth year in a row the an-
nual CAMA meeting has grown and
proven that CAMA is capable of pro-
ducing a quality scientific program
that meets the needs of the aviation
medical examiner on an interna-
tional level. I will also, at this point,
put in a word for next year's meet-
ing in Seattle, where the theme will
be one of a neuro/psych nature.
Begin your p l ann ing
now to attend and do
not miss out on a posi-
tive experience.
I am now half-way
through my term as your
President. I indicated last
year that I had two main
issues to address: improving commu-
nication and focusing on increasing
CAMA as an educational resource for
the AME. I believe that the first has
been achieved. The FlightPhysicietn
is doing well and keeping you regu-
larly updated. Members of the Board
have discussed several educational
improvements and we hope to begin
some of these initiatives during this
next year.
Have a healthy and safe Thanks-
giving and a joyous holiday season.
ff
Award Winners Announced at Annual Meeting
At the annual Civil AviationMedical Association meeting
held this year in Amsterdam, two
distinguished members were hon-
ored with the Association's highest
awards for outstanding accomplish-
ments in the field of aviation
medicine.
Bird Award
Per-Johan Cappelen, MD, of
Sandnes, Norway, received the Bird
Award. We will have his picture and
more information in the next issue
of the Flight Physician.
President's Award
This year, the Civil
Aviation Medical
Association's second-
highest award was
presented to Warren
S. S i lberman, DO,
MPH, manager of the
FAA's Aerospace
Medical Certification
Division.
Dr. Silberman is a
long-time member of
Dr. Silberman
the Association and
was cited by CAMA
president Robin E.
Dodge, MD, for a
"constant wil l ing-
ness" to support and
participate in CAMA
meetings, and for Dr.
Silberman's "un-
bounded enthusiasm
for the field of avia-
tion medicine."
FP
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When Your Eyes Deceive
BY DAVID BRYMAN, DO
SENIOR AVIATION MEDICAL EXAMINER
Of all our senses used in flying,vision is by far the most im-portant. Vision gives us all the
data needed to monitor instruments,
traffic, and cockpit activities. More im-
portantly, it determines visual references
for takeoffs and landing approaches. Our
visual system supplies nearly 90 percent
of our ability towards orientation.
Being aware of our visual percep-
tion is as important as knowing the
circumstances where our vision is not
reliable. In other words , we need to
realize when our eyes deceive us. The
weakest link in flying is not the ma-
chine we fly but the human who op-
erates it. We know that more than 70
percent of accidents are human-factor
related. Visual illusions are just one
of those factors. This article will re-
fresh your knowledge to some of the
more common visual illusions.
From a visual perspective, illusions
are mostly the result of light rays be-
ing distorted as they pass through air
containing dust, fog, haze, rain, snow,
and pollutants. These various compo-
nents refract (or bend) the light rays
before it reaches the eye. The result is
poorly focused objects and distorted
visual cues. This affects the pilot's abil-
ity to judge an object's size, shape, dis-
tance, and speed.
At altitude, the pilot's brain must
interpret visual images and cues from
a great distance. Some of these cues
allow us to compare one object to an-
other, as well as an object's size to its
velocity. For example, a 727 appears to
be moving faster at take off than a larger
747. Visual cues also allow us to com-
pare different textures, gradients (loss
of detail at greater distances), illumi-
nation perspective, and apparent
Being aware of our visual
perception is as important as
knowing the circumstances
where our vision is not
reliable.
foreshortening (a circle appears as an
ellipse at an angle). Many other con-
ditions can confuse visual perception
of any object such as haze, fog, rain,
mist, and smoke.
On August 13, 1977, a Dassault
DA-20 Falcon jet was substantially
damaged when it landed short of the
runway at the Blue Grass Airport
(LEX) in Lexington, Kentucky.
Night meteorological conditions
prevailed for the cargo flight conducted
under part 135. At the time of land-
ing, visibility was 2l/2 miles in heavy
rain and mist.
The copilot stated that the airplane
was never below the glide slope during
the approach.
But, after passing decision height,
the pilot had allowed the aircraft to
descend below the glide slope. The air-
plane landed hard on a grass bank
about 13 feet short of the runway.
The approach end of the runway was
about 34 feet lower than the highest
point of the runway, about 4500 feet
from the approach end. The aeronau-
tical manual stated, "An up sloping
runway, upsloping terrain, or both, can
create the illusion that the aircraft is at
a higher altitude than it actually is. The
pilot who does not recognize this illu-
sion will fly a lower approach."
The pilot above landed short due to
an illusion called slope illusion. This il-
lusion can be deadly, particularly if the
Continued on pave 11
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New Members
CAM A we/comes these new members to our growing family of aeromedical colleagues
Karen Alexander, MD
21 Redwood Drive
Newtown, PA 18940-3124
Phone 215-497-8424
Family Practice AME
Carl Anderson, MD
10693 Brixton Lane
Fisher, IN 46038-8706
Phone 317-849-7259
Occ. Medicine AME
Khairul Anuar, MD
MAS Med. Center
Gr. Floor Adm. 1 Bldg.
Sultan Abdul Aziz Shah Airport
47200 Slubnag, Malalysia
Eric Ashman, MD
8426-B Metzger Ave.
Ellmendorf AFB, AK 99506-2505
Phone 907-580-2524
Neurology Pilot AME
Philip }. Baney, MD
3212 Kutztown Road
Laureldale, PA 19605-2661
Phone 610-929-3380
Family Practice AME
E. G. Beeftink, MD
Diamantlaan 1
2132 WV Hoofddorp
The Netherlands
Michael Belding, MD
5 Belding Road
Barre, VT 05641
Phone 804-476-5048
Pilot AME
M.B. Biltaji, MD
Chief Aviation Medicine
CAA, P.O. Box 7547
Amman, Jordan
Lars Boman, MD
Lyeksele Hosp.Dept. Surgery
Llycksele, Sweden
Ryan Cantwell, MD
55 S. Medical Dr., Suite 300
Marietta, GA 30060-1165
Phone 770-427-2457
Internal Med.
John R. Chaffee, MD
32018 23rd Ave. S.
Federal Way, WA 98003-6031
Phone 253-839-3030
Family Practice
Richard F. Cooper, MD
18100 ShadbrookDr.
Northville, MI 48167-1821
Phone 248-349-5332
Radiology Pilot
AME
AME
AME
John T. Cope, MD
3060 Highway 17
Sautee, GA 30571-3003
Phone 706-878-4631
Internal Med.
Mark A. Crissman, MD
214 E. Elm St.
Graham, NC 27253-3022
Phone 336-226-2448
Family Practice
Bryan Davis, MD
3000 East 9th
Winfield, KS 67156
Phone 602-221-9500
Family Practice Pilot
Theodore Delbridge, MD
1363 Spreadiry Oak Dr.
Pittsburg, PA 15220
Phone 412-400-1158
Emergency Med. Pilot
Chandami D. Fernando, MD
707 Alexander Rd., Suite 201
Princeton, NJ 08540-6331
Phone 609-919-0009
Internal Med.
Jack Freidel, MD
107 Bridgeway St., Suite 100
Aurora, IN 47001-1378
Phone 812-926-3815
Family Practice Pilot
Jeffrey G. Garber, MD
420 Lowell Dr.
Huntsville, AL 35801-3754
Phone 256-535-5944
Family Practice Pilot
Matthew J. Caspar, MD
P.O. Box 2286
Wrangell, AK 99929-2286
Phone 907-874-7000
Family Practice
Devi P. Gollapudi, MD
47 Route 46
Hackettstown, NJ 07840-2642
Phone 908-852-8750
Internal Med.
Paula M. Gregory, DO
5157 Patriot Drive
Stone Mt., GA 30087-1421
Phone 770-908-9170
Family Practice
Steven J. Halm, DO
520 Maple Ave., Suite A
Reidsville, NC 27320-4650
Phone 336-634-3902
Internal/Pediatrics Pilot
Howard Hammett, DO
2942 Fenner St.
Mariette, MI 48453-1028
Phone 989-635-3875
AME Internal/Occ. Med. Pilot AME
Sharon C. Hathaway, MD
P.O. Box 562
Arden, NC 28704-0562
Phone 828-650-0409
AME Internal/Occ. Med. AME
Christer V. Hedenberg, MD
Previa, P.O. Box 20
S-19545 Stockholm Arlan, Sweden
A M I . Gregory L. Hopkins, MD
Rt. 3 Box 420
Cochran, GA 31014-8733
Phone 478-934-0550
Family Practice Pilot AME
AME Allen V. Hurt, MD
511 E. 20 l hSt.
Farmington, NM 87401-2105
Phone 505-566-1915
Occupational Med. AME
AME Marta Jacenyik, MD
103 Nightingale Ln.
Gujlf Breeze, FL 32561-7205
Phone 850-932-8600
Family Practice AME
AME Knus Jessen, MD
P.O. Box 150
Kastrup, DK-2770 Denmark
Vanessa Johnson, MD
1603 Commerce Rd.
AME Richmond, VA 23224-7501
Phone 804-230-6600
Family Practice AME
John J. Kuncaitis, MD
4885 Martin Rd.
AME Duluth, MN 55803-8202
Phone 218-727-1913
Family Practice AME
George Y. Kunze, MD
222 Alexender St., Suite 3100
AME Rochester, NY 14507-4043
Phone 585-325-2390
GI Pilot AME
Steven Lampert, MD
18555 N. 79'hAve, # B-108
AME Glendale, AZ 85308-8372
Phone 623-773-2828
Family Practice Pilot AME
Michael J. Landolf, MD
10804 Sagehurst PL.
AME Raleigh, NC 27614-7540
Phone 919-848-0880
Internal/Occ. Med. AME
.
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Joan Jorge Leite, MD
Rua Sergipe Sao Paulo
44lc j l l lA
San Pa;ulo, Brazil 01243-001
Phone 55-11-366-0404
Cardiology AME
Darryl Lesoski, MD, MPH
550 Munson Ave.
Traverse City.MI 49686-3580
Phone 231-935-8590
Occupational Med. AME
Edward Lloys, MD
3825 Cherokee St.
Kennesaw, GA 30144-2085
Phone 770-422-1400
Family Medicine AME
Daniel Lussenhop, MD
Park Nikollet Airport Clinic
7550 34th Ave. South
Minneapolis, MN 55450-0000
Phone: 952-993-9700
Occupational Med. AME
Keith K. Ly, DO
2312 N. 134th ST., Suite 1
Seattle, WA 98133-7852
Phone 206-363-6021
Family Practice AME
Susan M. Mahoney, MD
620 University Rd.
Friday Harbor,
WA 98250-9299
Phone 360-378-2141
Family Practice Pilot AME
Shannon Mobley, DO
205 N. Main
Bellevue, WA 49021-1233
Phone 269-763-9416
Family Practice Pilot AME
Aliasghar Mohyuddin, MD
1780 Hanshaw Rd.
Ithaca, NY 14850-9105
Phone 607-257-5858
Internal Med. AME
Jesse Monestersky, DO, MPH
NAMI (RAM) 340 Hulse Rd.
Pensacola, FL 32508-1092
Phone 850-452-4178
Aviation Medicine AME
Erik Norberg, MD
Previa, P.O. Box 20
Stockholm Arlanda, S-19045
Sweden
Stephen R. Nord, MD
5635 W. Las Positas Blvd.
Suite 401
Pleasanton, CA 94588-4076
Phone 925-520-0055
Intemal/Occ. Med AME
New Members (continued)
Karen K. Phillips, MD, MPH
1000 W/ 'O' St., Suite A
Lincoln, NE 68528-1300
Phone 402-475-6656
Occupational Med.
Matthew Quick, MD
11005 188th Ave. East
Benney Lake, WA 98390-6028
Phone 253-863-3194
Family Practice
Douglas M. Radman, MD
5785 Mealock Bridge PKWY
Alphareha, GA 30022
Phone 678-475-9100
Family Practice
Carlos M. Rodas, MD
Medical Department Chief
CAA, El Salwador
Phone 523-295-0433
Internal Medicine
Annette Ruge, MD
Licensing Div. Central JAA
P.O. Box 3000
KA Hjoofddorp 2130
The Netherlands
Ronaldo Schkolnik, MD
1600 N. Oak St., Apt. 810
Arlington, VA 22209-2754
Phone 703-524-8981
Ansthesiology Pilot
G.R. Shetty, MD
New Medical Center Hospital
P.O. Box 6222
Adu Dhabi, U.A.E.
E. Esther Shittu, MD
Nigerian College of Aviation
Zaria, Nigeria
Phone 234-069-334377
Internal Med.
Michael Smelser, MD
267 McMahon Rd.
Ramer, TN 38367-5149
Phone 713-645-7750
Internal Med. Pilot
Shanon Smith, MD
2836 Willowick TR.
Owens Cross,AL 35763-
Phone 256-517-7000
Occupational Med.
Ype Smit, MD
1st Clinic, P.O. Box 2651
Dar Es Salaan, Tanzani
Joseph J. Soler, MD
P.O. Box 460723
Aurora, CO 80046-0723
Phone 303-371-7263
Family Practice
AME
AME
AME
AME
AME
AME
AME
AME
Maria V. Soto, DO
3645 Ridge Mill Drive
Columbus, OH 43026-7752
Phone 614-777-8060
Family Practice AME
Gerald Surya, MD
JFK Aor[prt Dldg.14 W, #14A
Jamaca, NY 11430
Phone 768-656-1245
Internal Medicine AME
A.H.W. van der Linde, MD
Adr. Lacle Bldg. 5.
Oranjestad, Aruba
Dougal Watson, MD
Civil Aviation Authority
1 Market Grove
Lower Hujtt, New Zealand
Daryl Wilkins, DO
P.O. Box 569
Linden, CA 95236-0569
Phone 209-887-3342
Internal Medicine Pilot AME
Bruce R. Williams, MD
1012 Professional Lane
Enterprise, AL 36330-2085
Phone 334-347-3404
Internal Medicine AME
AME
CAMA 2002 from page 1
outstanding presentations on
cabin air, cosmic radiation,
travel medications, infectious
diseases, and bioterrorism.
The meeting was capped by a
tour of the Aerospace Physi-
ology Center at Soesterberg.
Members left the meeting
with praise for the program di-
rectors, your president, Dr.
Robin Dodge, and the execu-
tive vice-president, Jim Harris.
Plan for Next Year
Your next CAMA annual
meeting will be in Seattle,
Wash., on October 9-12,
2003. Plan to be there—or
miss another memorable Civil
Aviation Medical Association
meeting. FP
November 2002
Airplanes and
Biological
Terrorism
BY DAVID BRYMAN, DO
My reason for discussing the potential use of general
aviation aircraft by terrorists is not to alarm pilots or the
public, but to create awareness so we can all be better
prepared and educated.
I think of single engine
airplanes, I think of waking
up early on a beautiful summer
morning and going to the Scottsdale
Airport with Joe, my flying buddy.
We "fire up" one of the Cessnas and
leap into the clear blue sky. We may
be heading to one of the local air-
ports for breakfast or simply taking
in a bird's eye view of our magnifi-
cent state. Few of us give much
thought to our freedom to do so.. .or
at least little was given until the hor-
rific events of September 11th.
To me, flying airplanes has always
been associated with thoughts of
pleasure and recreation. We pilots
have enjoyed incredible freedom to
roam the skies virtually at will.
Shortly following the attack on our
country, general aviation (GA) was
restricted throughout the US, prima-
rily (but by no means only) in Class
B airspace, due to fears that terror-
ists might infiltrate one or more of
our 6,000 GA airports. This fear was
heightened when a troubled young
student pilot flew a Cessna 172 into
a Tampa, FL, bank building. Even
though he had no terrorist ties, and
the small plane caused little damage,
the incident definitely caused a great
deal of concern in both flying and
non-flying communities.
The potential for using an aircraft
as a weapon of destruction has be-
come tangible since the events of Sep-
tember llth. As a physician and an
aviator, I feel it is prudent to con-
sider the scenario so that we can edu-
cate and prepare our military, as well
as our medical community, to re-
spond appropriately.
Although chemical and biologi-
cal agents can be released in a wide
variety of ways from a great many
platforms (with varying effective-
ness), reasons to consider aircraft
for such attacks in the US are their
versatility, abundance, and avail-
ability. Even if the risk is small or
unlikely, just the possibility of a
terrorist attack using an aircraft to
disperse biological or chemical
weapons could be devastating psy-
chologically, if not physically.
As a physician, I ask myself:
Would our hospitals and medical
community be prepared for such an
assault? Would the average physician
recognize the early stages of a bio-
logical attack? For example, in a busy
emergency department in the height
of flu season, would a physician con-
sider a severe case of pneumonia as
being caused by pneumonic plague?
Could the average doctor make the
immediate distinction between small-
pox and chicken pox? Both produce
rash and fever. In smallpox, the fever
and rash begin approximately 12-14
days after exposure. The rash looks
similar to chicken pox, although
more dense and prominent on the
face. It then spreads to the extremi-
ties and trunk. The mortality rate is
30 percent in patients not previously
vaccinated. The disease is highly
contagious. Contaminated bed lin-
ens or clothing can also spread
smallpox. A person should be vac-
cinated within 3-4 days of exposure
to protect against a fatal outcome.
Vaccine supply is limited (though
improving) and can itself result in
serious complications.
American healthcare workers
and physicians must maintain con-
stant vigilance in watching for pat-
terns and considering biological
terrorism as a cause of unexplained
illnesses in multiple patients. For
example, a high number of patients
with severe respiratory illnesses or
deaths should prompt further in-
vestigation.
Biological weapons include any
device that one can use to inten-
tionally spread disease to a general
population. An aircraft flying over
a major metropolitan area deliver-
ing a biological agent could pro-
duce illness in thousands of people
within days or weeks of an attack.
(Releasing such an agent into the
ventilation system of a closed envi-
ronment would be far more effec-
tive. —ed.) Patients will require vac-
cines or antibiotics if approptiate.
In some cases, isolation (quaran-
tine) may be needed to help stop
the spread of the disease.
A possible end result might be a
mass epidemic that would over-
whelm our medical resources. The
most serious biological weapons
include smallpox, anthrax, and
plague. Other potential biological
weapons include botulism, tulare-
mia, and viruses that cause hemor-
rhagic fever.
Unlike smallpox, anthrax does
not spread from person to person.
The clinical signs usually appear
between two and 43 days after ex-
posure. The disease may manifest
in one of three forms in humans:
cutaneous (skin), inhalat ion
Continued on page 12
STEREO OPTICAL, A TRUSTED NAME IN
VISION SCREENING FOR OVER 50 YEARS,
OPTE(f 2000/2500 VISION TESTER FEATURES
Forehead Rest Pressure Bar
Ensures proper patient position.
(Includes disposable forehead tissues.)
Controlled Lighting
For the most accurate
color vision testing
available.
Peripheral Test (Optional)
Test vision on a horizontal
plane. Stimuli at 85, 70,
and 55 degrees temporal
and nasal.
Distance/Near Lens Systems
Two separate testing ports
for accurate distance and near testing.
Test at 32 Inches for
intermediate testing.*
Lightweight, Portable
Built In handle for easy
transport.
Side Access Doors
For easy patient/instructor
interaction.
Near/Far Point Indicators
illuminates at proper position
to verify test selection.
Tilt Activator
Height adjustable to
accommodate all patients.
FJUL TEST PACKAGE
SLIDE # 1 Peripheral Test Slide
SLIDE # 2** Distance Letter Acuity Monocular/Binocular (20/200-20/20)
SLIDE # 3** Pseudoisochromatic Color Perception
SLIDE # 4** Near Letter Acuity Monocular/Binocular (20/100-20/20)
SLIDE # 5** Lateral Phoria (1 Diopter Increments)
SLIDE # 6** Vertical Phoria (1/2 Diopter Increments)
SLIDE # 7 Stereo Depth Perception (400-20 Seconds of Arc)
SLIDE* 8 Fusion
SLIDE # 9 Distance Tumbling "E" Acuity Monocular/Binocular (20/200-20/20)
SLIDE #10 Tumbling "E" Color Perception
SLIDE #11 Muscle Balance (Combination Lateral & Vertical Phoria)
SLIDE #12 Distance Allen Test (20/100-20/30)
* This is a requirement for all airmen over the age of 50.
** These tests are required for F.A.A. vision exam.
OpMc » a registered trademark of Stereo Optical Co.. Inc., Chicago It
Optoc 2500 Viston lester is mtnutoctufwl under U.S. Patent«,453.51 S.
For the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis (SAR)and perennial allergic rhinitis (PAR)
in patients 12 years of age and older, as well as for the symptomatic relief of pruritus, reduction in the number
of hives, and size of hives, in patients with chronic idiopathic urticaria (CIU) 12 years of age and older
When treating SAR, PAR, and CIU, prescribe...
Powerful relie liui h the 24th hour
With an excellent safety profile
I Nonsedating—no precautions regarding activities
requiring mental alertness
I Safe for use in seasonal allergic rhinitis patients
with concomitant mild to moderate asthma
• No clinically relevant drug interactions or effects on QTC
— In studies with erythromycin, ketoconazole, azithromycin,
fluoxetine, and cimetidine
I Neither food nor grapefruit juice affected bioavailability
I The FAA medically qualifies pilots and air traffic controllers
using the product under special conditions
In allergic rhinitis, the most commonly reported adverse In chronic idiopathic urticaria, the most commonly
events included pharyngitis (4.1 %, placebo 2.0%), reported adverse events included headache
dry mouth (3.0%, placebo 1.9%), and fatigue (2.1%, (14%, placebo 13%), nausea (5%, placebo 2%),
placebo 1.2%). and fatigue (5%, placebo 1 %).
(desloratadine)™9L,
Please see brief summary of Prescribing Information on following page.
CLARINEX®
(desloratadine)
TABLETS
Brief Summary (For full Prescribing Information, see package insert.)
INDICATIONS AND USAGE: Allergic Rhinitis: CLARINEX Tablets 5 mg are indicat-
ed for the relief of the nasal and non-nasal symptoms of allergic rhinitis (seasonal
and perennial) in patients 12 years of age and older.
Chronic Idiopathic Urticaria: CLARINEX Tablets are indicated for the symptomatic
relief of pruritus, reduction in the number of hives, and size of hives, in patients with
chronic idiopathic urticaria 12 years of age and older.
CONTRAINDICATIONS: CLARINEX Tablets 5 mg are contraindicated in patients
who are hypersensitive to this medication or to any of its ingredients, or to lorata-
dine.
PRECAUTIONS: Carcinogenesis, Mutagenesis, Impairment of Fertility: The car-
cinogenic potential of desloratadine was assessed using loratadine studies. In an
18-month study in mice and a 2-year study in rats, loratadine was administered in
the diet at doses up to 40 mg/kg/day in mice (estimated desloratadine and deslor-
atadine metabolite exposures were approximately 3 times the AUC in humans at the
recommended daily oral dose) and 25 mg/kg/day in rats (estimated desloratadine
and desloratadine metabolite exposures were approximately 30 times the AUC in
humans at the recommended daily oral dose). Male mice given 40 mg/kg/day
loratadine had a significantly higher incidence of hepatocellular tumors (combined
adenomas and carcinomas) than concurrent controls. In rats, a significantly higher
incidence of hepatocellular tumors (combined adenomas and carcinomas) was
observed in males given 10 mg/kg/day and in males and females given
25 mg/kg/day. The estimated desloratadine and desloratadine metabolite exposures
of rats given 10 mg/kg of loratadine were approximately 7 times the AUC in humans
at the recommended daily oral dose. The clinical significance of these findings dur-
ing long-term use of desloratadine is not known.
In genotoxicity studies with desloratadine, there was no evidence of genotoxic
potential in a reverse mutation assay (Salmonella/E. coli mammalian microsome
bacterial mutagenicity assay) or in two assays for chromosomal aberrations
(human peripheral blood lymphocyte clastogenicity assay and mouse bone marrow
micronucleus assay).
There was no effect on female fertility in rats at desloratadine doses up to
24 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were
approximately 130 times the AUC in humans at the recommended daily oral dose). A
male specific decrease in fertility, demonstrated by reduced female conception rates,
decreased sperm numbers and motility, and histopathologic testicular changes,
occurred at an oral desloratadine dose of 12 mg/kg in rats (estimated desloratadine
exposures were approximately 45 times the AUC in humans at the recommended
daily oral dose). Desloratadine had no effect on fertility in rats at an oral dose of 3
mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were
approximately 8 times the AUC in humans at the recommended daily oral dose).
Pregnancy Category C: Desloratadine was not teratogenic in rats at doses up to
48 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures
were approximately 210 times the AUC in humans at the recommended daily oral
dose) or in rabbits at doses up to 60 mg/kg/day (estimated desloratadine exposures
were approximately 230 times the AUC in humans at the recommended daily oral
dose). In a separate study, an increase in pre-implantation loss and a decreased
number of implantations and fetuses were noted in female rats at 24 mg/kg (esti-
mated desloratadine and desloratadine metabolite exposures were approximately
120 times the AUC in humans at the recommended daily oral dose). Reduced body
weight and slow righting reflex were reported in pups at doses of 9 mg/kg/day or
greater (estimated desloratadine and desloratadine metabolite exposures were
approximately 50 times or greater than the AUC in humans at the recommended
daily oral dose). Desloratadine had no effect on pup development at an oral dose of
3 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were
approximately 7 times the AUC in humans at the recommended daily oral dose).
There are, however, no adequate and well-controlled studies in pregnant women.
Because animal reproduction studies are not always predictive of human response,
desloratadine should be used during pregnancy only if clearly needed.
Nursing Mothers: Desloratadine passes into breast milk, therefore a decision
should be made whether to discontinue nursing or to discontinue desloratadine,
taking into account the importance of the drug to the mother.
Pediatric Use: The safety and effectiveness of CLARINEX Tablets in pediatric
patients under 12 years of age have not been established.
Geriatric Use: Clinical studies of desloratadine did not include sufficient numbers
of subjects aged 65 and over to determine whether they respond differently from
younger subjects. Other reported clinical experience has not identified differences
between the elderly and younger patients. In general, dose selection for an elderly
patient should be cautious, reflecting the greater frequency of decreased hepatic,
renal, or cardiac function, and of concomitant disease or other drug therapy, (see
CLINICAL PHARMACOLOGY - Special Populations)
Information for Patients: Patients should be instructed to use CLARINEX Tablets
as directed. As there are no food effects on bioavailability, patients can be instruct-
ed that CLARINEX Tablets may be taken without regard to meals. Patients should
be advised not to increase the dose or dosing frequency as studies have not demon-
strated increased effectiveness at higher doses and somnolence may occur.
ADVERSE REACTIONS: Allergic Rhinitis: In multiple-dose placebo-controlled tri-
als, 2,834 patients received CLARINEX Tablets at doses of 2.5 mg to 20 mg daily,
of whom 1,655 patients received the recommended daily dose of 5 mg. In patients
receiving 5 mg daily, the rate of adverse events was similar between CLARINEX and
placebo-treated patients. The percent of patients who withdrew prematurely due to
adverse events was 2.4% in the CLARINEX group and 2.6% in the placebo group.
There were no serious adverse events in these trials in patients receiving deslor-
atadine. All adverse events that were reported by greater than or equal to 2% of
patients who received the recommended daily dose of CLARINEX Tablets (5.0 mg
once-daily), and that were more common with CLARINEX Tablet than placebo, are
listed in Table 5.
Table 5
Incidence of Adverse Events Reported by > 2% of Allergic Rhinitis
Patients in Placebo-Controlled, Multiple-Dose Clinical Trials
CLARINEX Tablets 5 mg Placebo
Adverse Experience (n=1,655) (n=1,652)
Pharyngitis
Dry Mouth
Myalgia
Fatigue
Somnolence
Dysmenorrhea
4.1%
3.0%
2.1%
2.1%
2.1%
2.1%
2.0%
1.9%
1.8%
1.2%
1.8%
1.6%
The frequency and magnitude of laboratory and electrocardiographic abnormali-
ties were similar in CLARINEX and placebo-treated patients.
There were no differences in adverse events for subgroups of patients as defined
by gender, age, or race.
Chronic Idiopathic Urticaria: In multiple-dose, placebo-controlled trials of chronic
idiopathic urticaria, 211 patients received CLARINEX Tablets and 205 received
placebo. Adverse events that were reported by greater than or equal to 2% of
patients who received CLARINEX Tablets and that were more common with
CLARINEX than placebo were (rates for CLARINEX and placebo, respectively):
headache (14%, 13%), nausea (5%, 2%), fatigue (5%, 1%), dizziness (4%, 3%),
pharyngitis (3%, 2%), dyspepsia (3%, 1%), and myalgia (3%, 1%).
The following spontaneous adverse events have been reported during the mar-
keting of desloratadine: tachycardia, and rarely hypersensitiyity reactions (such as
rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis), and elevated liver
enzymes including bilirubin.
DRUG ABUSE AND DEPENDENCE: There is no information to indicate that abuse
or dependency occurs with CLARINEX Tablets.
OVERDOSAGE: Information regarding acute overdosage is limited to experience
from clinical trials conducted during the development of the CLARINEX product. In
a dose ranging trial, at doses of 10 mg and 20 mg/day somnolence was reported.
Single daily doses of 45 mg were given to normal male and female volunteers for
10 days. All ECGs obtained in this study were manually read in a blinded fashion by
a cardiologist. In CLARINEX-treated subjects, there was an increase in mean heart
rate of 9.2 bpm relative to placebo. The QT interval was corrected for heart rate
(QTC) by both the Bazett and Fridericia methods. Using the QTC (Bazett) there was a
mean increase of 8.1 msec in CLARINEX-treated subjects relative to placebo. Using
QTC (Fridericia) there was a mean increase of 0.4 msec in CLARINEX-treated sub-
jects relative to placebo. No clinically relevant adverse events were reported.
In the event of overdose, consider standard measures to remove any unabsorbed
drug. Symptomatic and supportive treatment is recommended. Desloratadine and
3-hydroxydesloratadine are not eliminated by hemodialysis.
Lethality occurred in rats at oral doses of 250 mg/kg or greater (estimated deslor-
atadine and desloratadine metabolite exposures were approximately 120 times the
AUC in humans at the recommended daily oral dose). The oral median lethal dose
in mice was 353 mg/kg (estimated desloratadine exposures were approximately
290 times the human daily oral dose on a mg/m2 basis). No deaths occurred at oral
doses up to 250 mg/kg in monkeys (estimated desloratadine exposures were
approximately 810 times the human daily oral dose on a mg/m2 basis).
Schering Corporation
Kenilworth, NJ 07033 USA
2/02 23882116T-JBS
U.S. Patent Nos. 4,659,716; 4,863,931; 4,804,666; 5,595,997; and 6,100,274.
Copyright © 2002, Schering Corporation. All rights reserved.
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Eyes from page 3
upsloping runway is associated with
upsloping terrain. The opposite case,
down sloping runway or terrain, re-
verses the illusion.
Another illusion common
to pilots is called featureless
terrain. This is common in
winter during a white out
with blowing snow or when
landing on a strip whose ap-
proach end is at the edge of
a calm lake. In this case, the
pilot will feel as if he is higher
than he actually is and, therefore,
flies a lower approach. This prob-
lem is much worse at night and is
commonly referred to as the black
hole illusion. The black hole illusion
occurs due to a lack of cues from the
peripheral vision on a night that has
no reference to the horizon such as
flight over water, or over terrain that
is dark except for runway lights.
The illusion is to be in a situation
other than straight-and-level flight,
especially if there is already the illu-
sion of sloping runway or city lights
on a rising terrain. Your seat position
may make you more or less likely to
get this effect. If your seat is too low
during a dark night, you will only be
able to see the runway lights if you
are on descent. You will set up a con-
stant angle of descent according to
your field of view. This illusion be-
gins a few miles out on final. The field
and lights will be foreshortened. The
runway field should rise in the field
of view as you approach closer; how-
ever, the view will remain constant due
to the steeper approach. The eye/brain
interpretation is that the constant fore-
shortened runway is an indication of
a constant angle approach. This is the
"everything is fine illusion" of the
black hole. The best way to counter-
act this illusion is to fly the instru-
ments. Make sure your altimeter is
set correctly, and realize that your
brain is telling you that you're higher
than you really are. You are better
off flying a full pattern than a long
straight-in approach, as the illusion
is less dramatic this way.
Illusions do not cause accidents; rather it
is the p/'/ot's reaction to the illusion that
precipitates the accident.
Another common illusion at night
is one called oculogyml. This illusion
occurs at night when the vision is
compromised. The pilot perceives the
apparent motion of a distant object
as a result of stimulation of the semi-
circular canals. For example, in the
early stages of a left turn, the target
appears to move rapidly to the left.
After the turn is established and
stopped, the object appears to move
in the opposite direction. The pilot
might not correct the aircraft unless
the instruments are used, and he is
convinced that he is tracking a mov-
ing illusion.
Autokinesis is another nighttime il-
lusion that affects a pilot's vision. This
occurs when the pilot perceives a sta-
tionary light to be moving. This is
more likely to occur if the pilot looks
at the light for several minutes rather
than just a glance. This moving illu-
sion can lead the pilot to follow it vi-
sually. The cause is the brain and eye's
attempt to find some other point of
reference in an otherwise featureless
visual field. Prevention is the realiza-
tion that the eye must focus on other
objects at varying distances, not fix-
ating on one target. In other words,
do the basic scanning we were all
taught when learning how to fly.
All pilots are susceptible to illusions
when any of our three flight senses
(visual, auditory, and kinesthetic) are
interpreted erroneously by our mind.
Remember, airplanes are made and de-
signed to fly, humans are not. We have
"software" designed specifically to in-
terpret motion, and our orientation is
on the ground not in the air.
Since visual illusions affect all
pilots, it should be obvious
that if one is less than healthy
because of such as the use of
any alcohol prior to flight, hy-
poglycemia, fatigue, illness,
hypoxemia, or use of any
medication, one would be at
much greater risk for these illusions.
Illusions do not cause accidents;
rather it is the pilot's reaction to the
illusion that precipitates the accident.
Knowing and recognizing the
power of visual illusions, a pilot should
anticipate and respect certain situa-
tions that would most likely result in
their existence such as night flight,
flight into adverse weather, or flight
over featureless terrain. It should be
obvious that the scan and cross-check
of instruments become a crucial part
of any flight.
I remember a recent flight to
Sedona (SEZ) in a Cessna 172. I no-
ticed I was high on the approach
about a quarter of a mile out and,
in fact, had to slip to avoid a go-
around. I realized the slope of the
runway, as well as the elevation of
the field in relationship to the ter-
rain caused this visual illusion. Had
I anticipated this visual illusion in
advance, I would have had more
time for breakfast, rather than the
time spent explaining to my passen-
gers why we approached the land-
ing sideways and what a slip was
used for.
My next Sedona landing was per-
fect, in my opinion. However, I know
now that if it looks too good to be
true, it just may be an illusion.
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Short Approaches
Cockpit Fatigue and
Pilot Stress
BY JAMES R. ALMAND, MD
E:ective pilot performance isiosely associated with manyhysiologic factors. This
article will attempt to relate fatigue
and stress in the aviation pilot
group and develop measures to
foresee, anticipate, avoid, prevent,
and hopefully, manage fatigue and
stress factors in the pilot.
The FAA's Civil Aerospace Medi-
cal Institute states that stress can be
defined as the sum of emotional and
biologic reaction to any adverse
physical, mental, or emotional inter-
nal/external condition that tends to
upset the body's natural balance.
There are many facets of this issue
— in all pilots the demands of life,
family, social, scheduling, recurrent
training, rest, illness, and even men-
tal or physical health in general all
play a significant role in pilot perfor-
mance. Overlay all these previous
factors ( or even one of the group)
with an acute event in flight in the
cockpit, and an immediate overload
of tasking of cockpit management
skills and performance might de-
velop. Combine again the previous
factors with the addition of crew
management conflict, bad weather,
unfamiliar approaches, minor (or
major) aircraft malfunctions, ATC
confusion, or an FAA jump-seater,
and the pilot's stress gauge might
exceed his maximum level.
A fast and stressful pace crowds the
aviator's Betz cells.
Stress in the aviator can occur both
in an acute situational exacerbation
or in a chronic ongoing state. It can
Continued on page 15
Airplanes and Biological Terrorism from page 6
(lungs), and gastrointestinal. For
inhalation anthrax the fatality rate
is more than 85 percent. Patients
dying of overwhelming infection
(sepsis) and or meningitis follow-
ing a flu-like condition should be
evaluated for possible anthrax. An-
thrax vaccine is not currently avail-
able for civilian use. (Its use in the
military remains controversial —ed.)
An epidemic of aerosol-dispersed
plague would produce symptoms
similar to severe pneumonia. Patients
would be seen in emergency rooms
or by their family doctors, and have
pneumonia-like, although much
more severe, symptoms usually asso-
ciated with blood in the sputum.
Plague must be treated early and
aggressively with antibiotics to as-
sure survivability. Plague can eas-
ily be transmitted from person to
person, so a mask must be used if
any face-to-face contact occurs at
less than 10 feet. No vaccine exists
for pneumonic plague.
In addition to biological weap-
ons, aircraft can also become plat-
forms for chemical terrorism at-
tacks. Such weapons include nerve
agents and toxic gases, and can pro-
duce symptoms of illness within
minutes to a couple of hours after
an attack. They would affect per-
sons directly exposed to the agent,
and antidotes (not antibiotics)
would be required in a very short
time to improve survivability.
It has been widely reported that
the terrorists involved in the Septem-
ber 11 th attacks had also looked into
training in and obtaining crop dust-
ers, presumably for use in a chemical
attack. Using a crop duster in this
manner could be potentially devas-
tating. If delivered from the air, nerve
gases—being heavier than air—
would descend upon an unsuspect-
ing population. In such an event,
physicians would need to recognize
the situation and provide appropri-
ate treatment as victims must be im-
mediately hosed off with large
amounts of water, and then be treated
with the appropriate antidotes.
Nerve agents will cause multiple
symptoms including: salivation,
tearing, nausea, vomiting, slow
heart rate, muscle pain, tremors,
weakness, seizures, and death.
Toxic gases usually cause throat
irritation, eye sensitivities, and con-
striction in the lungs. The patient
will usually die of lung failure and
lack of oxygen.
My reason for discussing the
potential use of general aviation
aircraft by terrorists is not to alarm
pilots or the public, but to create
awareness so we can all be better
prepared and educated. Developing
and improving our ability to rec-
ognize, diagnose, treat and prevent
diseases due to biological and
chemical weapons—however they
may be deployed—should continue
to be a national priority.
How can we as pilots help to keep
our airplanes from potential terror-
ists? The most important thing we
can do is to maintain a high situ-
ational awareness. Know who is fly-
ing the airplanes at our FBO, report
any suspicious activity immediately,
keep our own airplanes secure and
locked and perform thorough pre-
flight inspections. In doing so, we can
ensure that the freedoms we cherish
won't be used to seize an opportu-
nity by those with malicious intent.
ff
This article was previously published in America's Flyways and is reprinted here
with the permission of the author.
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CAMA CONSULTANTS
To our new members and as a reminder to all: This is a list of more experienced AMEs that have volunteered to help
with troublesome certification cases. For involved questions, E-mail or fax is preferred. This list is NOT for use by
airmen, but solely for AMEs within the CAMA membership.
Frank H. Austin, MD EST
Phone: 703- 471-1769
Fax: 703-450-3104
E-mail: FHAustin@aol.com
Charles A. Berry, MD CST
Phone: 713-978-7755
Fax: 713-978-5001
E-mail: docchuckb@aol.com
A. Duane Catterson, MD CST
Phone: 281-873-0111
Fax: 281-873-0660
E-mail: cattersib@worldnet.att.net
Marc C. Eidson, MD CST
Phone: 817-599-9472
Fax: 817- 599-9472
E-mail: MARK@EIDSON.ORG
A. J. Parmet, MD CST
Phone: 816-561-3480
Fax: 816-561-4043
E-mail: AJParmet@cysource.com
Gordon L. Hitter, DO MST
Phone: 520-776-9830
Fax: 513-751-5660
E-mail: gordon@rittaire.com
Robert A. Stein, MD EST
Phone: 513-751-0080
Fax: 513-751-5660
E-mail: Bobxtein47@aol.com
M. Young Stokes III, MD CST
Phone 903-465-6707
Fax: 903-465-6744
E-mail: mysiii@flash.net
James L. Tucker, MD EST
Phone: 256-329-7788
E-mail: JLTucker@mindspring.com
Mark Thoman, MD CST
Phone: 515-244-4229
Fax: 515-244-1131
E-mail: PAROl795@aol.com
John D. Hastings, MD CST
Phone: 918-747-7517
Fax: 918-742-7947
E-mail: hastings20@msn.com
H. Stacy Vereen, MD EST
Phone: 404-761-2166
Fax: 404-761-2168
E-mail: Stacyv@earthlink.net
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CIVIL AVIATION MEDICAL ASSOCIATION
Corporate and Sustaining Members
The financial resources of individual members alone cannot sustain the Association's pursuit of its broad goals
and objectives. Its forty-six year history is documented by innumerable contributions toward aviation health and
safety that have become a daily expectation by airline passengers worldwide. Support from private and commer-
cial sources is essential for CAMA to provide one of its most important functions: that of education. The follow-
ing support CAMA through corporate and sustaining memberships:
James R. Almand Jr., MD
Frank H. Austin Jr., MD
R.L. Bendixen, MD
Forrest M. Bird, MD, PhD
Stephen V.A. Blizzard, MD
Per-Johan Cappelen, MD
Frank J. Ceravolo, MD
Halford R. Conwell, MD
SUSTAINING MEMBERS
Gary E. Crump, PA.
Robin E. Dodge, MD
John D. Hastings, MD
Francis C. Hertzog, Jr. MD
Marlene K. Lambiaso, MD
Floyd F. McSpadden, MD
Hugh O'Neill, MD
Robert S. Poole, MD
Robert W. Rigg, MD
Gordon L. Ritter, DO
W. David Rummel, MD
M. Young Stokes III, MD
James L. Tucker Jr., MD
H. Stacy Vereen, MD
Albert van der Waag, Jr., MD
Alex M. Wolbrink, MD
Banyan International Corp.
P.O. Box 1779
Abilene, TX 70604-1779
Continental Airlines
9900 Richmond Ave.
Houston, TX 77210-4807
Data Transformation Corp.
108-D Greentree Road
Turnersville, NJ 08012
HP Heartstream
2401 4th Ave., Suite 500
Seattle, WA 98121-1436
CORPORATE MEMBERS
Medaire, Inc
1301 E. McDowell Rd, #204
Phoenix, AZ 85006-2665
Motara Instruments, Inc.
7866 North 86th Street
Milwaukee, WI 53224
Nonin Medical Inc.
2605 Fernbrook Lane North
Plymouth, MN 55447-4755
Percussion Aire Corp.
Forrest M. Bird, MD, Pres.
Sandpoint, ID 83864-0817
Rummel Eye Care, PC.
1022 Willow Creek Rd.
Prescott, AZ 86301-1642
Schering Corporation
Kenilworth, NJ 0733
Stereo Optical Company Inc.
Joseph F. Andera, President
Chicago, IL 60641
Titmus Optical
3311 Corporate Drive
Petersburg, VA 23805-9288
Voyager Air Center
Denison, TX
Harvey Watt & Co., Inc.
P.O. Box 20787
Atlanta, GA 30320
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Your Ex from page 1
primary objectives of civil aviation
medicine as a scientific discipline
are well defined:
1. to assist in the selection of per-
sons physically and mentally ca-
pable of performing critical
tasks under different opera-
tional and environmental con-
ditions, and
2. to continuously assess risk
analysis by early detection of
potentially incapacitating con-
ditions which could pose a
threat to flight safety.
In addition, an added responsi-
bility became clearly evident over
the last couple of years: the need to
take care of the health and welfare
of passengers.
Clinical aviation medical knowl-
edge has been substantially in-
creased by research and educational
programs conducted worldwide
over the last 40 years; the gained
understanding of the relations be-
tween humans, machines, and en-
vironments has profited from work
conducted in relation to the explo-
ration of space. The vast knowledge
existent should be made available
to the practitioners in charge of
implementation of the pertinent
regulations. Medical examiners, as
well as aviation medicine special-
ists are required by law to be pro-
vided with appropriate training.
In this context, good clinical
aviation medical knowledge should
be complemented with manage-
ment training, since within the
ideal theoretical situation, it has
become clear that programs are
needed to facilitate the relevant
"technology transfer" at managerial
levels. It has been universally ac-
cepted that human factors are of
significance in the context of flight
safety and that aviation medicine
doctors are responsible for safe-
guarding the medico-biological
components of the aviation sys-
tems.
Of great significance is the
present concern of unwarranted
groundings of license holders for
medical reasons (in which socio-
economic considerations play a
major role) or wrong assessment of
physical and mental fitness (in
which flight safety could be signifi-
cantly impaired). The urgent need
for equitable managerial decisions
has become significant. While ba-
sic clinical knowledge is readily
available and easily transferred, this
is not so when managerial decisions
take precedence over strict medical
matters.
Several significant examples of
matters with medical components
are found in issues such as duty
time and rest periods, upper-age
limits for flying personnel, cabin air
quality, medical supplies on board,
liability issues (need for a global
Good Samaritan law), and smok-
ing restrictions.
All in all, we have done well over
the last quarter of a century; we
should continue to improve our
knowledge to provide outstanding
aeromedical advice to the aviation
system.
In closing, it has been a real plea-
sure to serve as CAMA's president
during important developmental
periods of "our" Association.
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Cockpit Fatigue from page 12
be approached by the flyer in innu-
merable ways, (usually productively)
through training of repetitive skills,
mentally directed psychologic
patterns, or placing prior or ongoing
current stress factors into the pilot's
mental background in response to im-
mediate emergent factors.
Which pilot will exceed his psy-
chologic limits in an overly (or less
stressful) situation? School House
cockpit simulation cannot predict
when CRM (cockpit risk manage-
ment) and SA (situational awareness)
will fall apart. Will these potentially
eventual episodes fall to the task of
the accident board?
Some recent medical authorities
have added a challenge to the stress
definition by asking, "Is this a bio-
logic reaction, or does the brain's
dopamine (etc.) reaction command
the human brain to respond by de-
veloping stress?" These newer, debat-
able theories involve options such as
chemical cellular exchanges, neuro-
logic self-tendered effects, brain re-
sponses to chemical or psychologic
stress, and even the elusive basic
chemical brain "computerization" of
how stress evolves and how the hu-
man brain concert responds in effect.
Is the human brain a large deposit of
positive and negative "bit forces"
combining to a response of con-
sciousness following a stressful cere-
bral input?
So — what to do? How to assess
each pilot. How to anticipate the
potential — How to prepare for and
avoid stress — How to protect each
pilot's performance — How to un-
derstand the individual's limits -
How to remain clear in extreme situ-
ations — How to be calm and cool.
This is where the "real pilot" emerges!
More (or less) to follow by 2003.
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Un The Horizon
Mid-Year Retreat Scheduled
The Board of Trustees and Officers of the Civil
Aviation Medical Association will hold its mid-year
retreat in Irving, Texas, on December 6 - 7 , 2002.
Any member who wishes to attend is cordially in-
vited to do so.
The retreat will be held at the Embassy Suites
DFW Airport South at 4650 West Airport Freeway,
Irving, Texas.
If you have suggestions or areas that the Associa-
tion should be involved in, please contact:
* CAMA President Robin Dodge, MD, E-mail
robin.dodge@wright.edu
4 or Executive Vice-President James L. Harris, E-mail
jimlharris@aol.com
FAA Aviation Medical Examiner
Seminar Schedule
2002
December 2-6 Oklahoma City, Okla. (Basic)
2003
January 10-12 Phoenix, Ariz. (Cardiology)
March 10-14 Oklahoma City, Okla. (Basic)
April 25-27 Atlanta, Ga. (Ophth/Otolaryn/Endocrin)
May 5-8 San Antonio, Texas (Neuro/Psychol/Psy)
June 9-13 Oklahoma City, Okla. (Basic)
For information, call your regional flight surgeon. To schedule
a seminar, call the FAA Civil Aerospace Medical Institute
AME Programs Office ( 405) 954-4830
Visit CAMA's Web Site: www.civilavmed.com
CAMA Headquarters
P.O. Box 23864
Oklahoma City, OK 73123-2864
